Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy-Reference-Cited by-同舟云学术

Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy

Published:2004-03 Issue:6 Volume:43 Page:1047-1055
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Julius Stevo,Alderman Michael H,Beevers Gareth,Dahlöf Björn,Devereux Richard B,Douglas Janice G,Edelman Jonathan M,Harris Katherine E,Kjeldsen Sverre E,Nesbitt Shawna,Randall Otelio S,Wright Jackson T

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE);Dahlöf;Lancet,2002

2. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE);Lindholm;Lancet,2002

3. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention for Endpoint Reduction (LIFE) substudy;Kjeldsen;JAMA,2002

4. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study;Dahlöf;Am J Hypertens,1997

5. Characteristics of 9194 patients with left ventricular hypertrophy;Dahlöf;Hypertension,1998

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Le concept de race : serpent de mer de la pratique médicale;Médecine & Droit;2024-09

2. Identification of three distinct cell populations for urate excretion in human kidneys;The Journal of Physiological Sciences;2024-01-02

3. Identification of three distinct cell populations for urate excretion in human kidney;2023-06-29

4. Genetic heterogeneity in cardiovascular disease across ancestries: Insights for mechanisms and therapeutic intervention;Cambridge Prisms: Precision Medicine;2023

5. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial;American Heart Journal;2022-12